Artal Group S.A. Allogene Therapeutics, Inc. Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$24.82 - $31.4 $2.48 Million - $3.14 Million	-100,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $2.61 Million - $3.3 Million	-100,000 Reduced 50.0%	100,000 $2.73 Million
Q2 2019 Aug 09, 2019	SELL	$25.56 - $31.09 $5.11 Million - $6.22 Million	-200,000 Reduced 50.0%	200,000 $5.37 Million
Q4 2018 Feb 11, 2019	BUY	$22.5 - $33.3 $9 Million - $13.3 Million	400,000 New	400,000 $10.8 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $275M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.